Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management

T. Warnecke, K-H. Schäfer, I. Claus and 2 more

npj Parkinson's Disease · 2022 · Review · CC BY

doi:10.1038/s41531-022-00295-x

Abstract

Growing evidence suggests an increasing significance for the extent of gastrointestinal tract (GIT) dysfunction in Parkinson’s disease (PD). Most patients suffer from GIT symptoms, including dysphagia, sialorrhea, bloating, nausea, vomiting, gastroparesis, and constipation during the disease course. The underlying pathomechanisms of this α-synucleinopathy play an important role in disease development and progression, i.e., early accumulation of Lewy pathology in the enteric and central nervous systems is implicated in pharyngeal discoordination, esophageal and gastric motility/peristalsis impairment, chronic pain, altered intestinal permeability and autonomic dysfunction of the colon, with subsequent constipation. Severe complications, including malnutrition, dehydration, insufficient drug effects, aspiration pneumonia, intestinal obstruction, and megacolon, frequently result in hospitalization. Sophisticated diagnostic tools are now available that permit more detailed examination of specific GIT impairment patterns. Furthermore, novel treatment approaches have been evaluated, although high-level evidence trials are often missing. Finally, the burgeoning literature devoted to the GIT microbiome reveals its importance for neurologists. We review current knowledge about GIT pathoanatomy, pathophysiology, diagnosis, and treatment in PD and provide recommendations for management in daily practice.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Thirty years ago, gastrointestinal tract (GIT) symptoms in Parkinson’s disease (PD) played a subordinate role in clinical practice of most neurologists and movement disorders specialists, despite the existence of numerous very early clinical reports and neuropathological findings that clearly provided evidence of relevant GIT involvement–. Although GIT dysfunction can precede somatomotor symptoms by up to 20 years– and impact negatively on quality of life,, clinicians mainly focused on the ‘classical’ motor symptomatology at that time. It was not until the late 1980s and early 1990s that the number of clinical studies and neuropathology publications about the complex interaction of PD and the GIT begin to increase, thereby, also stimulating the interest of clinical neurologists for this topic–. After 2000, the quest for explanations regarding the potential role of the GIT and the peripheral nervous system in the pathogenesis of PD gained momentum owing to the work by the Braak group, among others–. Thus, one finds in PubMed for the period 1960–1969 eleven (keywords ‘Parkinson’ and ‘dysphagia’) and four (keywords ‘Parkinson’ and ‘constipation’) publications, from 1970 to 1979 twenty (‘Parkinson’ and ‘dysphagia’) and seven (‘Parkinson’ and ‘constipation’) publications, as opposed to more than ten entries per year beginning in 1992 and 2003, and, alone for the year 2020, 109 articles (‘Parkinson’ and ‘dysphagia’) and 93 (‘Parkinson’ and ‘constipation’) (<parkinson dysphagia - Search Results - PubMed (nih.gov) and< parkinson constipation - Search Results - PubMed (nih.gov)).

Today, GIT research is a promising and still growing field of inquiry and continues to provide neurologists and movement disorders specialists with novel and valuable data that can help to better understand the complexity of PD. At this point, we still have a multitude of jigsaw puzzle pieces that must be carefully pieced together. Periodic review articles are intended to serve as the basis for future work,,,. Here, we provide an overview of the latest knowledge, hypotheses, and debates about the pathology, pathophysiology, diagnostic methods for oropharyngeal and esophageal affection as well as impairment of the lower GIT, including a summary of current treatment strategies from an interdisciplinary standpoint. These might be helpful for neurologists, speech- and language therapists, and other clinicians in their daily work with PD patients and PD-associated GIT dysfunction.

Anatomy: gastrointestinal tract and associated brain areas: central control of gastrointestinal motility

The entire GIT is one of the major gateways for extrinsic influences upon the human body. It is autonomously innervated by the largest part of the peripheral nervous system, the so-called enteric nervous system (ENS), which contains several hundreds of neurons and even more glial cells. Both neurons and glial cell populations have a variety similar to that found in the brain. Neurons consist of motoneurons, secretomotor-, or interneurons that express acetylecholine, nitric oxide synthase, catecholamines, GABA, or a broad range of neuropeptides–. Glial cells can be found in at least four different morphologies and chemical codings, expressing S100B, the reactive gliosis marker GFAP, PDGFRα, or proteolipid-protein-1,. Both neurons and glial cells form complex networks that populate in ganglionic and aganglionic plexus the complete gut wall from esophagus to anus and from serosa to mucosal layer.

The ENS varies significantly along the gut axis, analogue to the distinct functional differences between the individual gut segments. Different neuronal subtypes and glial cells form neuronal circuits that allow the autonomous regulation of gastrointestinal motility. Although the gut works independently, there is a varying influence of the central nervous system (CNS) via several additional extrinsic inputs, of which the vagus nerve is the largest. The vagus nerve is part of the so-called brain-gut-axis that connects the CNS with the GIT. The brain-gut-axis consists of two main routes between the two organs. One is based on humoral factors, such as cytokines, hormones, or even bacterial metabolites from the gut microbiome, whereas the other is a hard-wired connection: the vagus nerve. The vagus nerve contains up to 50,000 fibers that run in both directions, the afferent ones being the majority with ~90% of all fibers. While the afferent fibers deliver information from the gut, the efferent fibers provide parasympathetic motor stimuli that originate in two brainstem nuclei, first the dorsal motor nucleus of the vagus and, second, the ambiguus nucleus, which both contribute to gastrointestinal motility. Additionally to this direct input from the brainstem, there are several routes of influence represented, i.e., by sympathetic fibers from prevertebral ganglia that connect the gut with thoracic segments of the spinal cord.

The CNS influence upon gastrointestinal motility is dependent on the location. While there is a considerable impact on both esophagus and stomach, the gut becomes more independent in the small and large intestine, where autonomous reflex circuits control smooth muscle activity, local blood flow, or secretion and absorption along the mucosal barrier. Interestingly, recent studies provide evidence that there are neural connections between the vagal nuclei and various areas of the cortex that influence stomach motility and, thus, might be affected in PD, as demonstrated in a rat model. Especially the latter might explain the top-down gastrointestinal symptoms in PD. Based on the dual-hit hypothesis, there will also be a bottom-up process, possibly initiated by local inflammation and a compromised mucosal barrier, that allows gut content, including lipopolysaccharides, short chain fatty acids (SCFA) or other bacterial metabolites to enter the gut wall. In PD patients, the mucosal barrier is compromised and corresponding markers, such as calprotectin, can be found in the feces. There is a vast amount of evidence that the microbiome in PD patients is disturbed, combined with an alteration of SCFAs. Recent studies demonstrate the existence of neuronal circuits that monitor the microbiome or its metabolites report to the CNS or lead to modification of the innervation. These findings open up perspectives for using the gut, its intrinsic nervous system, the mucosal barrier, or the microbiome as therapeutic targets.

Pathology: alpha-synucleinopathy in the GIT of incidental Lewy body disease and Parkinson’s disease

Lewy pathology (LP, Lewy bodies, Lewy neurites) in prodromal PD (at autopsy, incidental Lewy body disease, ILBD–) and in sporadic PD occurs throughout the human GIT,,–. Interpretation of ENS histological slides from intestinal biopsies requires caution because immunocytochemical protocols vary considerably, and α-synuclein immunoreactivity must be distinguished from α-synuclein aggregates (LP) and α-synuclein aggregating species. As staged cases show, LP exists in the olfactory bulb, spinal cord, peripheral autonomic ganglia, submandibular gland, cardiac nerves, and ENS before it appears in the substantia nigra, pars compacta, and before neuronal loss occurs there,–. The aggregated α-synuclein lesions are not transient.

One of the largest studies examined a wide range of organs from 92 autopsied individuals, including 17 PD, 7 ILBD, and 23 controls. In pure PD, LP was found in the GIT of 64.7% (11/17), peripheral vagal nerve (pN. X) of 73.3%, and sympathetic trunk of 80% of cases. In ILBD, 14.2% (1/7) showed LP in the GIT and 28.57% in the pN. X. 50% of the ILBD group also displayed LP in the sympathetic trunk. A decreasing ENS rostral-caudal immunostaining gradient was seen, corroborating an earlier report: The upper GIT, i.e., distal esophagus followed by the stomach, tended to display the highest pathological burdens; both sites are directly controlled by parasympathetic preganglionic fibers of the vagus nerve,, (see section “Anatomy: gastrointestinal tract and associated brain areas: central control of gastrointestinal motility” above). Although there were no ‘ENS-only’ (i.e., ‘ENS-first’) cases in the cohort, the authors surmised that “the findings of the present study are not incompatible with a GI entry for PD, ILBD and DLB”. In a subsequent investigation of pN. X tissue, they concluded that “the results [i.e., LP in 10/18 ILBD and 42/44 PD subjects; no LP in 49 controls] support initiation of Lewy-type alpha-synucleinopathy in the brain, with early, in some cases preclinical, subsequent progression to the peripheral nervous system”. However, a lack of α-synuclein immunopositivity in the true control (as opposed to ILBD) group is not surprising [see also] and, in any event, in 55.56% (ILBD) and 95.45% (manifest PD) of cases the pN. X was involved.

The 2010 study may have a selection bias because, to assess the relative LP frequency in the periphery, the ultimate choice of regions for further study was reduced to those with “a greater likelihood to have positive staining” rather than shared innervation or neuronal circuitries. In addition, for the majority of their cases, the authors examined only a single slide for each ENS subdivision. Relevant ENS-related autonomic structures, e.g., the lumbar prevertebral celiac ganglion (sympathetic innervation of the esophagus, stomach, duodenum, pancreas, liver) and spinal cord SPS, but also the appendix vermiformis and superior mesenteric ganglion,,, were not included.

Results from investigations performed to date on large cohorts show, despite divergent findings from smaller studies,, that 0% of ILBD cases displayed LP in the ENS in the absence of brain lesions–. Of the prodromal PD cases analyzed by Stockholm et al., 44% (17/39) of subsequent PD patients displayed no ENS LP, and not even all manifest PD cases from autopsy-based studies had ENS involvement,,, see also ref.. The heterogeneity of findings obtained from such studies is complicated not only by differences in immunocytochemical staining techniques and study design (cohort sampling size and stratification, retrospective vs. longitudinal), but also by dissection protocols. Borghammer & Van Den Berge point out that the human GIT “measures ~8–10 m at post-mortem and has a geometric surface area of at least 7000 cm2. Thus, many hundreds of microscopy slides are required to rule out… gut pathology with any degree of confidence”. Similarly, pN. X specimens necessarily come from a very limited portion of the entire nerve,,,,, and multiple sections from both vagal trunks would be required to ascertain whether LP is present or absent in a given individual.

The argument that autopsy-based studies report only rare cases of LP in the ENS in the absence of brain LP does not eliminate the possibility of an ENS and/or peripheral nervous system origin for PD (ILBD), or of LP spread from the ENS to the brain,,,. That a potential anatomical pathway from intrinsic ENS neurons to the pN. X exists, receives support from the fact that the myenteric plexus, epithelial enteroendocrine cells, and preganglionic portions of the N. X express normal α-synuclein,. Converging lines of evidence also support the idea of propagation via cell-to-cell transsynaptic transmission of misfolded α-synuclein into recipient cells; there, misfolded α-synuclein can recruit native α-synuclein and become a template for development of pathological aggregates–. Formalin-fixed tissue from the stomach is capable of limited to robust seeding in ILBD (5/8 cases), PD (10/12 cases), and controls (2/9).

Overexpressed human α-synuclein and human α-synuclein lysates in animal models can mediate cellular dysfunction, as well as pathological spreading (seeding) along the pN. X bidirectionally–, and anatomical connectivities,– make both directionalities conceivable in human α-synucleinopathy (Fig. 1). The latest findings in the appendix vermiformis of 46/48 ILBD cases, indicate that additional ‘conduits’ for such pathological α-synuclein transport could exist (Fig. 1).

An awareness is gradually emerging that the presence of LP in the GIT and its patterns of progression may well differ between various PD subpopulations and in ILBD,,,,. Borghammer & Van Den Berge postulated the existence of a ‘PNS-first Lewy body disorder phenotype’, wherein early pathology in the peripheral autonomic nervous system might spread along retrograde connectivities to nuclei of the lower brainstem that contribute to rapid-eye-sleep (REM) regulation (Fig. 1). This intriguing hypothesis, drawing on insights gleaned from idiopathic REM sleep behavioral disorder (RBD) research–, could also be tested neuropathologically, provided tissue from RBD patients were still available, in autopsy cohorts staged according to the 2003 PD staging protocol and including early ILBD–.

Prevalence of dysphagia

Oropharyngeal dysphagia is a common and often disabling clinical manifestation in PD. Recent meta-analysis estimates the prevalence of oropharyngeal dysphagia up to 82% during the course of the disease. However, only 20–40% of patients are aware of their swallowing dysfunction, and only less than 10% report their complaint spontaneously, which might result from early pharyngeal hyposensibility,. Recent research has led to the conclusion that oropharyngeal dysphagia is not only a late-stage PD symptom but can occur during any stage of the disease, including the preclinical or prodromal stages,,. Therefore, a comprehensive examination of oropharyngeal swallowing function should be performed regularly, even in early disease stages, when defined clinical predictors (see below) are present.

Pathophysiology

In contrast to all other parts of the GIT, the oropharynx is not only innervated by the involuntary ENS but is also controlled from voluntarily triggered mechanisms of skeletal muscle movements. Thus, some additional pathophysiological mechanisms play a role that are also relevant for other somatomotor symptoms of PD, such as bradykinesia or tremor:Accumulation of Lewy pathology (see section “Pathology: alpha-synucleinopathy in the GIT of incidental Lewy body disease and Parkinson’s disease” above) takes place not only in the substantia nigra but also in various non-dopaminergic swallowing-relevant brainstem and cortical areas.Putamen and globus pallidus are activated bilaterally during normal swallowing. Therefore, lack of dopamine in the striatum of PD patients may impair this part of the supramedullary swallowing network.Peripheral mechanisms might be also involved as indicated by α-synuclein deposits in the peripheral sensory and motor nerves of the larynx as well as disease-induced neuromuscular alterations of pharyngeal muscles–. Substance P plays an important role in these peripheral oropharyngeal mechanisms.

Accumulation of Lewy pathology (see section “Pathology: alpha-synucleinopathy in the GIT of incidental Lewy body disease and Parkinson’s disease” above) takes place not only in the substantia nigra but also in various non-dopaminergic swallowing-relevant brainstem and cortical areas.

Putamen and globus pallidus are activated bilaterally during normal swallowing. Therefore, lack of dopamine in the striatum of PD patients may impair this part of the supramedullary swallowing network.

Peripheral mechanisms might be also involved as indicated by α-synuclein deposits in the peripheral sensory and motor nerves of the larynx as well as disease-induced neuromuscular alterations of pharyngeal muscles–. Substance P plays an important role in these peripheral oropharyngeal mechanisms.

Substance P (SP)

SP is an ubiquitous neuropeptide in the nervous system, with immunoactive fibers having been detected in the laryngeal nerves, epithelium, and basal membrane of pharyngeal mucosa, especially on the surface of the epiglottis. SP mediates the response to local stimuli in the pharyngeal mucosa and thereby enhances the swallow and cough reflexes. A reduction of substance P, found in PD patients’ sputum, is postulated to lead to a disturbance of protective reflexes and, ultimately, silent aspiration. Reduced saliva concentrations of substance P may also be a predictor for the presence of early pharyngeal swallowing dysfunction. Table 1 provides an overview of PD-related oropharyngeal dysphagia clinical manifestations and postulated pathomechanisms.

Main pathological findings

The main phenotype characteristic of PD-related dysphagia is insufficient pharyngeal bolus clearing, with residues predominant located in the valleculae, in addition to pharyngolaryngeal movement disorders, above all pharyngeal bradykinesia. Silent aspiration is also a frequent clinical manifestation, even in early stages, but the risk increases with disease duration. In an analogy to freezing of gait with similar pathophysiologic mechanisms, a recent study described the presence of oropharyngeal freezing resulting in a temporally missing or delayed swallowing reflex.

Dual task situations (i.e., cognitive or somatomotor tasks) are challenging to swallowing functional reserve capacities and therefore should be integrated into standard instrumental swallowing evaluations, (Fig. 2). Furthermore, retention of medications in the hypopharynx for long periods of time may account for erratic absorption of levodopa with an insufficient or unpredictable clinical response to oral medication (Fig. 3). An association of delayed on-phenomena with pharyngeal residues could have been shown as well. In a recent study, substantially impaired ability to swallow tablets or capsules was found in 28% (n = 33/118) of patients at all stages of the disease. Capsules were the easiest to swallow, whereas oval tablets were the most difficult.

Clinical predictors

The following clinical conditions have been linked to oropharyngeal dysphagia in PD and can be considered predictors,,:Hoehn and Yahr stage ≥IIIRelevant weight lossBody Mass Index (BMI) ≤20 kg/m2Severe drooling or sialorrheaDementia

Hoehn and Yahr stage ≥III

Relevant weight loss

Body Mass Index (BMI) ≤20 kg/m2

Severe drooling or sialorrhea

Dementia

Another major problem for PD patients is drooling,. Sialorrhea in PD patients usually does not result from an increased production of saliva but from a reduced spontaneous swallowing rate (48/h vs. 71/h) and/or from oropharyngeal dysphagia with a reduced ability to swallow saliva. The extent of sialorrhea correlates with the severity of PD-related dysphagia.

Screening-tools

Questionnaires and a specific water swallow test may be used as screening tools:The Swallowing Disturbance Questionnaire (SDQ) with a sensitivity of 80.5% and a specificity of 81.3% is simple to apply using a score of 15 dysphagia-associated questions to detect PD-related dysphagia. A score >10 recommends further dysphagia diagnostic (max. score 44.5). Additionally, the patient-rated Radboud Oral Motor Inventory for Parkinson’s disease (ROMP) questionnaire is used for assessment of speech, swallowing, and saliva control.The Munich Dysphagia Test—Parkinson’s disease (MDT-PD) with a sensitivity of 82% and a specificity of 71% was designed to detect milder forms of dysphagia without aspiration risk, although its usefulness as a screening tool for aspiration events is controversial. A French version is also available.The Non-Motor Symptoms Questionnaire (NMS-Quest; Question 3: “difficulty swallowing food or drink or problems with choking”) and the Movement Disorder Society—Unified Parkinson’s disease rating scale (MDS-UPDRS; Question 2.3 of the UPDRS II: “problems swallowing pills or eating meals”) each also include one question about swallowing difficulties,. However, in a recent study, NMS and MDS-UPDRS were identified as unreliable tools for detecting previous aspiration.Normal water tests that are useful for diagnosing severe dysphagia, e.g., in stroke patients, are not reliable screening tools for PD-related dysphagia when compared with instrumental diagnostic tools. A detection of a ‘wet voice’ after different bolus consistencies showed a too low sensitivity to be a solid marker of penetration/aspiration in PD. Therefore, a modified water test was developed to evaluate the stimulability of drinking by using a maximum performance test (maximum swallowing volume <20 mL, maximum swallowing speed <10 mL/s). Nonetheless, in a more recent study, swallowing speed was found to be prone to methodological errors and not unsuitable as a screening instrument to predict aspiration in PD patients.

The Swallowing Disturbance Questionnaire (SDQ) with a sensitivity of 80.5% and a specificity of 81.3% is simple to apply using a score of 15 dysphagia-associated questions to detect PD-related dysphagia. A score >10 recommends further dysphagia diagnostic (max. score 44.5). Additionally, the patient-rated Radboud Oral Motor Inventory for Parkinson’s disease (ROMP) questionnaire is used for assessment of speech, swallowing, and saliva control.

The Munich Dysphagia Test—Parkinson’s disease (MDT-PD) with a sensitivity of 82% and a specificity of 71% was designed to detect milder forms of dysphagia without aspiration risk, although its usefulness as a screening tool for aspiration events is controversial. A French version is also available.

The Non-Motor Symptoms Questionnaire (NMS-Quest; Question 3: “difficulty swallowing food or drink or problems with choking”) and the Movement Disorder Society—Unified Parkinson’s disease rating scale (MDS-UPDRS; Question 2.3 of the UPDRS II: “problems swallowing pills or eating meals”) each also include one question about swallowing difficulties,. However, in a recent study, NMS and MDS-UPDRS were identified as unreliable tools for detecting previous aspiration.

Normal water tests that are useful for diagnosing severe dysphagia, e.g., in stroke patients, are not reliable screening tools for PD-related dysphagia when compared with instrumental diagnostic tools. A detection of a ‘wet voice’ after different bolus consistencies showed a too low sensitivity to be a solid marker of penetration/aspiration in PD. Therefore, a modified water test was developed to evaluate the stimulability of drinking by using a maximum performance test (maximum swallowing volume <20 mL, maximum swallowing speed <10 mL/s). Nonetheless, in a more recent study, swallowing speed was found to be prone to methodological errors and not unsuitable as a screening instrument to predict aspiration in PD patients.

Instrumental diagnostic tools

Flexible Endoscopic Evaluation of Swallowing (FEES) and Videofluoroscopic Swallowing Study are both considered to be the gold standard for evaluating oropharyngeal dysphagia,. These instrumental tools should be applied in cases of unclear and severe PD-associated dysphagia, especially to detect silent aspiration as well as specific dysphagia phenotypes,.

Therapeutic management

Over the years, a number of studies have provided evidence-based recommendations for treatment of oropharyngeal dysphagia,,,. Swallowing therapy, especially as performed by speech and language therapists, and other specific therapeutic options might help to improve oropharyngeal swallowing impairment:

Pharmacotherapy

The effects of dopaminergic medication and levodopa on swallowing function and its role in dysphagia treatment are controversially discussed–. Oropharyngeal swallowing parameters with good levodopa-responsiveness could be pharyngeal residue (especially in the valleculae), penetration, and oral as well as pharyngeal transit times,. Furthermore, some studies indicate positive effects of the dopamine agonists apomorphine and transdermal rotigotine–. As such, an examination whether an improvement in swallowing function could be achieved by increasing or optimizing dopaminergic medication should be performed on a case-by-case basis, i.e., by using the FEES-Levodopa-Test. In this test, three salient parameters (premature spillage, penetration/aspiration events, and residues, each tested with liquid, semisolid, and solid food consistencies) are assessed in off- and on-stage conditions performing a specific score. A score improvement of >30% indicates levodopa responsiveness of dysphagia. Subsequently, in such cases, optimizing dopaminergic medication should be considered. Furthermore, levodopa-carbidopa intestinal gel (LCIG) infusion therapy might be capable of alleviating pharyngeal bradykinesia and premature bolus spillage.

Deep brain stimulation (DBS)

To date, detailed information about the effects of DBS on swallowing function in PD patients remain limited,. Using stimulation of the subthalamicus nucleus (STN), low-frequency stimulations (i.e., 60 Hz) may have a beneficial effect on swallowing dysfunction in patients with freezing of gait,, whereas high-frequency stimulation might result in beneficial, no, or detrimental effects. A short-term improvement (lower aspiration rate) was indicated as well but without confirmation in the long-term observation. Simultaneous STN and substantia nigra (SNr) stimulation seem to have no additional beneficial effect on dysphagia compared with conventional STN stimulation, but swallowing function does not deteriorate as a result.

Neuromuscular electrical stimulation (NMES)

The use of NMES in PD patients seems to have no measurable benefit,. A recent study using new electrode placement methods indicates increased hyoid bone movement and reduced aspiration risks, but NMES cannot be recommended for PD dysphagia treatment at the present time.

Behavioral swallowing therapy

Because of heterogenous study populations and therapeutic methods as well as different outcome measures, general recommendations for non-pharmacological treatment are difficult to provide. However, some therapeutic strategies are promising for individual treatment of specific patterns of PD-related dysphagia: Thickened liquids and the chin-tuck maneuver might help to prevent liquid aspiration,. The Lee Silverman Voice Treatment (LVST®), originally developed for treatment of PD-associated dysarthria, can also improve swallowing function, although controlled clinical trials are not yet available and the effects are unspecific. With regard to therapeutic strategies, dual task situations should be avoided in real-life circumstances to focus attention on swallowing performance. Two larger, randomized placebo-controlled studies showed a positive effect on swallowing safety and efficiency in PD patients who had performed a 4-week- expiratory muscle strength training regimen,. Video-assisted swallowing therapy and specific swallowing skill training using surface electromyography might also be helpful for providing biofeedback to patients,. In general, every affected PD patient should receive a detailed examination of swallowing disturbance patterns resulting in an individual training program based on available therapeutic methods. The efficacy of the method(s) selected should be confirmed via instrumental testing.

Treatment of sialorrhea

Parkinson-related sialorrhea can be managed effectively with injections of botulinum toxin A or B into the parotid and submandibular glands. Another pharmacological treatment option might be the application of the anticholinergic drug glycopyrrolate because it crosses the blood-brain barrier and therefore does not have central anticholinergic side-effects. In addition, gum chewing also helps to improve PD-related sialorrhea in the short term but without maintaining a long-term effect.

Prevalence and main clinical findings

The prevalence of impaired gastric emptying in PD ranges from 70 to 100% and may be present in both early and advanced stages,. Major clinical manifestations include nausea, vomiting, early satiety, and postprandial fullness, and these can lead to weight loss, malnutrition, and dehydration. Furthermore, there is growing evidence for a significant relationship between delayed gastric emptying and levodopa pharmacokinetics leading to drug-response fluctuations with delayed or missed on-phases after medication intake.

Esophageal motility disorders appear to occur very early and even in premotor stages of PD,. A hypotensive peristalsis of the tubular esophagus occurs most frequently and early in the disease course, whereas in later stages diffuse esophageal spasms and multiple contractions may develop. However, primary opening disorders of the upper esophageal sphincter are rare.

Diagnostic management

Impaired gastric emptying is defined as >60% retention at 2 h postprandially and/or >10% retention at 4 h after ingestion of a radioactive technetium Tc 99m-labeled solid food. Other quantitative methods are the use of breath tests with nonradioactive 13C-sodium octanoate bound into a solid meal, or real time visualization by magnetic resonance imaging and electrogastrography. Because clinical evaluation is difficult, diagnostic examination of esophageal motility disorders nowadays is normally performed by using High Resolution Manometry to detect esophageal alterations.

Therapeutic management

Therapeutic options for managing PD-associated esophageal motility disorders are rare to date. A pilot study indicates a possible usefulness of botulinum toxin injections for treatment of esophageal spasms, but more evidence is needed. STN stimulation might also improve esophageal motility. The use of capsaicin seems to be capable of improving esophageal motility as well as upper esophageal sphincter contraction, and it might be a promising tool for further treatment,. In gastroparesis, the increase of levodopa dosage may impair delayed gastric emptying. Pharmacotherapy options using domperidone might be useful but are said to increase the risk of a long QT syndrome. Recent studies have indicated possible positive effects by using nitzatidine or ghrelin agonists but these require further evaluation. Benefits from botulinum toxin injection in the pyloric sphincter and possible use of STN-DBS have been reported as well,. However, LCIG (with or without entacapone application), subcutaneous apomorphin, and the rotigotine patch are helpful solutions for bypassing the GIT and therefore could be administered in cases of clinically relevant effects of esophageal spasms as well as gastroparesis on somatomotor symptoms.

Summary/Practical algorithm for management

Disturbances of the upper GIT in PD, especially oropharyngeal dysphagia, are complex syndromes that occur early in disease duration but often remain unnoticed until severe complications, such as aspiration pneumonia, develop. Accordingly, standardized and early diagnostic approaches as well as focused treatment of specific dysphagia patterns are required to help affected individuals. Table 2 provides a summary of the most relevant clinical manifestations of upper GIT impairment and feasible treatment approaches.

Prevalence of constipation

Since initially being mentioned by James Parkinson, constipation has been considered a very frequent symptom that occurs in up to 80% of PD patients,,–. As is often the case, constipation is described as the most frequent autonomic symptom,,. Notably, healthy people with constipation complaints, including delayed passage of stools, hard stools, or a sensation of incomplete evacuation, have shown a greater risk for subsequently developing PD–. This fits well the neuropathological studies published by Braak and coworkers, (see chapter 3). Constipation is currently considered one of the most relevant early signs of PD, and its frequency seems to be higher than the subjective complaints,,,–. The GIT may even play an important role in PD pathogenesis,, and as a prognostic factor, inasmuch as a significant relationship between constipation severity and progression to dementia has recently been demonstrated,. Additional studies are needed to determine whether a similar relationship exists in patients who develop dementia with Lewy bodies (DLB).

Pathophysiology

Medications, reduced physical movement, a reduced muscle tone in the diaphragm and abdominal musculature, and reduced intake of fibers and liquids have been advanced as causes for constipation. Beginning with the earliest studies and onwards, anticholinergic agents have been particularly related to severe constipating effects, including even the development of a megacolon. Constipation in PD is definitely disease-related. It was described long before any specific therapy had been found,, and many studies of yet untreated patients were able to demonstrate delayed transit,. It is much more probable that, in PD patients, a delayed transit plays an intrinsic and prominent role, and that constipation even can be exacerbated by the medical treatment itself,.

The causes underlying the delayed transit are most probably degenerative changes involving Lewy pathology located centrally, including the spinal cord intermediolateral nucleus, and peripherally extending from the upper esophagus to the rectum in the Auerbach plexus (myenteric plexus) and Meissner plexus (submucous plexus),,,. Additionally, anismus, a failure of relaxation, or involuntary contractions of the anal sphincters during defecation (extremely rare!), can lead to so-called “outlet” constipation.

Diagnostic management

Because constipation can develop into a megacolon, pseudo-obstruction, or volvulus, adequate diagnosis is essential. Unfortunately, a megacolon usually remains asymptomatic, with the exception of the singular symptom of constipation, although an ileus followed by surgery and colon perforation have been described as megalcolon consequences. Surprisingly, despite the existence of severe constipation at the time of presentation, patients seldom report this problem spontaneously, often because of embarrassment, which indicates that it is most probably underdiagnosed.

A simple method during the diagnostic work-up involves administering radiopaque markers (ROM) (Fig. 4) as the gold standard diagnostic test: Abdominal X-rays are taken at defined time intervals to identify the retained numbers of ingested ROMs to calculate colonic transit time. Alternatively, a gamma camera can be used to track the movements of radioisotope test meals or capsules at specified time points for quantitative evaluation of scintigraphic colonic transit times. For orientation, it is also useful to ask patients to eat poppy seed cake and then note when the poppy seeds are excreted.

Although there is no gold standard method for the assessment of outlet constipation, defecography is widely preferred. It involves the instillation of barium in the rectum, and subjects are then asked to empty it during recording of a cinematic film. Anorectal dysfunction can also be assessed by external anal sphincter electromyography, a balloon distension and expulsion test, and anorectal manometry.

Therapeutic management

At present, there are no specific guidelines for the management of PD-associated constipation available. A fiber-rich diet, psyllium as a bulk laxative, stool softener, and sufficient liquid-intake have high therapeutic value in treating constipation, but regular physical exercise and physical therapy are also advisable. Exclusion of aggravating factors, such as anticholinergics, should be considered. Unfortunately, these measures are only useful in mild or moderate cases. In many instances, a colonic transit of more than 7 days is reported, and no improvement of colonic transit can be achieved by the various therapeutic options owing to the upper threshold. In this case, additional medication must be prescibed. An effect of domperidone in the upper GIT has not been shown for constipation.

Stimulants, such as bisacodyl, sodium picosulfate, and senna are safe and helpful. In addition, stimulant laxatives and osmotic laxatives are recommended. The best results to date are achieved with macrogol,. A disadvantage of lactulose is flatulence. Positive data are also available for therapies with probiotics and probiotic fibers,.

There are still no studies on the effects of modern prokinetic agents, such as serotonin (5-HT4) agonists, e.g., mosapride. In the meantime, prucaloprid has been approved for severe constipation and may be administered to PD patients, although specific studies in this population are still lacking. Several new drugs, including relamorelin (ghrelin agonist), and chlorid channel activators, such as linaclotide, lubipprostone, and plenacanatide,– are in discussion. In rare cases of anismus, we recommend botulinum toxin injections.

Excursus: the role of the GIT microbiome

The GIT microbiome in PD has been intensively researched in recent years,,,,–. By applying metagenomic and next-generation sequencing procedures, it is now possible to distinguish PD patients from healthy individuals, at a very early disease stage by means of individually altered microbiota. There may even be a ‘prodromal’ GIT microbiome because a microbial shift has been found, for instance, in patients with RBD. In one large cohort, reduced GIT microbial diversity in PD patients correlated significantly with greater GIT symptom severity in comparison to controls, and evidence exists for an ‘enteric pro-inflammatory profile’ in PD,. Intestinal dysbiosis and small intestinal bacterial overgrowth in PD patients might increase intestinal barrier permeability, thereby triggering excessive stimulation of the innate immune system and systemic inflammation, mechanisms possibly involved in the initiation of α-synuclein deposition–. According to this scenario, α-synuclein expression in the GIT would reflect an immune defense mechanism, which is further supported by the finding that the protein is capable of triggering T cell responses that may also potentiate neurodegeneration.

At present, interpretation of the available findings is difficult because a great variety of factors can influence the microbial configuration of the GIT. For example, evaluation of the GIT microbiome in patients undergoing treatment for PD is still of limited use, inasmuch as levodopa and other antiparkinson medications act upon the intestinal flora,,, and, at least in a subset of patients, the opposite is also the true. In addition, particularly for PD, it cannot be clarified retrospectively whether the altered GIT microbiome is the cause or the effect of motility disturbances, such as severe constipation,,, and the association between the microbiome and neuroinflammation in PD still remains unclear,,,, in part because the cohorts studied to date, with few notable exceptions,, have been small,. Finally, if the microbiome and its metabolites were to play a key pathogenetic role in PD, then considerable differences should be observable between populations on different continents owing simply to dietary variability, but this has not proved to be the case. Nonetheless, it is imperative, going forward, to examine not only the precise role of the GIT microbiome and the effects a targeted diet and probiotics might have on PD patients,, but also the potential advantages and adverse side effects associated with fecal microbiotica transplantation–.

Final conclusions/practical algorithm for management

Dysfunction of the upper GIT in PD, especially oropharyngeal dysphagia, are complex syndromes occurring early in disease that often remain unnoticed until severe complications, such as aspiration pneumonia, become manifest. In the lower GIT, constipation is a widespread and debilitating symptom with the potential of leading to severe bowel complications and even cognitive dysfunction.

In closing, standardized and early diagnostic approaches together with continuous and long-term treatment are necessary to help patients (Table 2).

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

References 232

  1. 1.

    Eadie MJ, Tyrer JH. Alimentary disorder in parkinsonism. Australas. Ann. Med. 1965;14:13-22.

    Not in our library10.1111/imj.1965.14.1.13

  2. 2.

    Eadie MJ, Tyrer JH. Radiological abnormalities of the upper part of the alimentary tract in Parkinsonism. Australas. Ann. Med. 1965;14:23-27.

    Not in our library10.1111/imj.1965.14.1.23

  3. 3.

    den Hartog Jager WA, Bethlem J. The distribution of Lewy bodies in the central and autonomic nervous systems in idiopathic paralysis agitans. J. Neurol. Neurosurg. Psychiatry. 1960;23:283-290.

    Not in our library10.1136/jnnp.23.4.283

  4. 4.

    Coelho M, et al. Late-stage Parkinson’s disease: the Barcelona and Lisbon cohort. J. Neurol. 2010;257:1524-1532.

    Not in our library10.1007/s00415-010-5566-8

  5. 5.

    Jost WH. Gastrointestinal dysfunction in Parkinson’s disease. J. Neurol. Sci. 2010;289:69-73.

    Not in our library10.1016/j.jns.2009.08.020

  6. 6.

    Fasano A, Visanji NP, Liu LW, Lang AE, Pfeiffer RF. Gastrointestinal dysfunction in Parkinson’s disease. Lancet Neurol. 2015;14:625-639.

    Not in our library10.1016/s1474-4422(15)00007-1

  7. 7.

    Lubomski M, Rushworth RL, Tisch S. Hospitalisation and comorbidities in Parkinson’s disease: a large Australian retrospective study. J. Neurol. Neurosurg. Psychiatry. 2015;86:324-330.

    Not in our library10.1136/jnnp-2014-307822

  8. 8.

    Lubomski M, Davis RL, Sue CM. Gastrointestinal dysfunction in Parkinson’s disease. J. Neurol. 2020;267:1377-1388.

    Not in our library10.1007/s00415-020-09723-5

  9. 9.

    Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta. Neuropathol. 1988;76:217-221.

    Not in our library10.1007/bf00687767

  10. 10.

    Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F. Parkinson’s disease: an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta. Neuropathol. 1990;79:581-583.

    Not in our library10.1007/bf00294234

  11. 11.

    Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F. Lewy bodies in the visceral autonomic nervous system in Parkinson’s disease. Adv. Neurol. 1993;60:609-612.

    Not in our library

  12. 12.

    Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson’s disease. Neurology. 1989;39:1309-1314.

    Not in our library10.1212/wnl.39.10.1309

  13. 13.

    Jost WH, Schimrigk K. Constipation in Parkinson’s disease. Klin. Wochenschr. 1991;69:906-909.

    Not in our library10.1007/bf01798536

  14. 14.

    Jost WH. Gastrointestinal motility problems in patients with Parkinson’s disease: effects of antiparkinsonian treatment and guidelines for management. Drugs Aging. 1997;10:249-258.

    Not in our library10.2165/00002512-199710040-00002

  15. 15.

    Edwards L, Quigley EMM, Hofman R, Pfeiffer RF. Gastrointestinal symptoms in Parkinson disease: 18-month follow-up study. Mov. Disord. 1993;8:83-86.

    Not in our library10.1002/mds.870080115

  16. 16.

    Braak H, Rüb U, Gai WP, Del Tredici K. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 2003;110:517-536.

    Not in our library10.1007/s00702-002-0808-2

  17. 17.

    Braak H, de Vos RAI, Bohl J, Del Tredici K. Gastric α-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease related brain pathology. Neurosci. Lett. 2006;396:67-72.

    Not in our library10.1016/j.neulet.2005.11.012

  18. 18.

    Langston JW. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann. Neurol. 2006;59:591-596.

    Not in our library10.1002/ana.20834

  19. 19.

    Cersósimo MG, et al. Gastrointestinal manifestations in Parkinson’s disease: prevalence and occurrence before motor symptoms. J. Neurol. 2013;260:1332-1338.

    Not in our library10.1007/s00415-012-6801-2

  20. 20.

    Klingelhoefer L, Reichmann H. Parkinson’s disease and gastrointestinal non motor symptoms: Diagnostic and therapeutic options – a practice guide. J. Parkinsons Dis. 2015;5:647-658.

    Not in our library10.3233/jpd-150574

  21. 21.

    Suttrup I, Warnecke T. Dysphagia in Parkinson’s disease. Dysphagia. 2016;31:24-32.

    Not in our library10.1007/s00455-015-9671-9

  22. 22.

    Furness JB, Callaghan BP, Rivera L, Cho HJ. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv. Exp. Med. Biol. 2014;817:39-71.

    Not in our library10.1007/978-1-4939-0897-4_3

  23. 23.

    Jessen KR. GABA and the enteric nervous system. A neurotransmitter function? Mol. Cell Biochem. 1981;38 Spec No:69-76.

    Not in our library10.1007/bf00235689

  24. 24.

    Hens J, Vanderwinden JM, De Laet MH, Scheuermann DW, Timmermans JP. Morphological and neurochemical identification of enteric neurones with mucosal projections in the human small intestine. J. Neurochem. 2001;76:464-471.

    Not in our library10.1046/j.1471-4159.2001.00032.x

  25. 25.

    Timmermans JP, Hens J, Adriaensen D. Outer submucous plexus: an intrinsic nerve network involved in both secretory and motility processes in the intestine of large mammals and humans. Anat. Rec. 2001;262:71-78.

    Not in our library10.1002/1097-0185(20010101)262:1<71::aid-ar1012>3.0.co;2-a

  26. 26.

    Qu ZD, et al. Immunohistochemical analysis of neuron types in the mouse small intestine. Cell Tissue Res. 2008;334:147-161.

    Not in our library10.1007/s00441-008-0684-7

  27. 27.

    Gulbransen BD, Sharkey KA. Novel functional roles for enteric glia in the gastrointestinal tract. Nat. Rev. Gastroenterol. Hepatol. 2012;9:625-632.

    Not in our library10.1038/nrgastro.2012.138

  28. 28.

    Grundmann D, et al. Enteric glia: S100, GFAP, and beyond. Anat. Rec. 2019;302:1333-1344.

    Not in our library10.1002/ar.24128

  29. 29.

    Spencer NJ, Hu H. Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility. Nat. Rev. Gastroenterol. Hepatol. 2020;17:338-351.

    Not in our library10.1038/s41575-020-0271-2

  30. 30.

    Endres K, Schäfer KH. Influence of commensal microbiota on the enteric nervous system and its role in neurodegenerative diseases. J. Innate Immun. 2018;10:172-180.

    Not in our library10.1159/000488629

  31. 31.

    Beyak, M. J., Bulmer, D., Jiang, W., Keating, W., Grundy, D. Extrinsic Sensory Afferent Nerves Innervating the Gastrointestinal Tract, Physiology of the Gastrointestinal Tract Ch. 25 In Physiology of the Gastrointestinal Tract, 4th ed (eds Leonard R. Johnson). (Academic Press, San Diego, 2006), pages 685–725.

    Not in our library

  32. 32.

    Travagli RA, Anselmi L. Vagal neurocircuitry and its influence on gastric motility. Nat. Rev. Gastroenterol. Hepatol. 2016;13:389-401.

    Not in our library10.1038/nrgastro.2016.76

  33. 33.

    Levinthal DJ, Strick PL. Multiple areas of the cerebral cortex influence the stomach. Proc. Natl Acad. Sci. USA. 2020;117:13078-13083.

    Not in our library10.1073/pnas.2002737117

  34. 34.

    Anselmi L, Toti L, Bove C, Hampton J, Travagli RA. A nigro-vagal pathway controls gastric motility and is affected in a rat model of parkinsonism. Gastroenterology. 2017;153:1581-1593.

    Not in our library10.1053/j.gastro.2017.08.069

  35. 35.

    Hawkes CH, Del Tredici K, Braak H. Parkinson’s disease: a dual hit hypothesis. Neuropathol. Appl. Neurobiol. 2007;33:599-614.

    Not in our library10.1111/j.1365-2990.2007.00874.x

  36. 36.

    Schwiertz A, et al. Fecal markers of intestinal inflammation and intestinal permeability are elevated in Parkinson’s disease. Parkinsonism Relat. Disord. 2018;50:104-107.

    Not in our library10.1016/j.parkreldis.2018.02.022

  37. 37.

    Boertjen M, Pereira PAB, Aho VTE, Scheperjans F. Increasing comparability and utility of gut microbiome studies in Parkinson’s disease: A systematic review. J. Parkinsons Dis. 2019;9:S297-S312.

    Not in our library10.3233/jpd-191711

  38. 38.

    Unger MM, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson’s disease and age-matched controls. Parkinsonism Relat. Disord. 2016;32:66-72.

    Not in our library10.1016/j.parkreldis.2016.08.019

  39. 39.

    Muller PA, et al. Microbiota modulate sympathetic neurons via a gut-brain circuit. Nature. 2020;583:441-446.

    Not in our library10.1038/s41586-020-2474-7

  40. 40.

    Dickson DW, et al. Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s disease. Acta Neuropathol. 2008;115:437-444.

    Not in our library10.1007/s00401-008-0345-7

  41. 41.

    Markesbery WR, Jicha GA, Liu H, Schmitt FA. Lewy body pathology in normal elderly subjects. J. Neuropathol. Exp. Neurol. 2009;68:816-822.

    Not in our library10.1097/nen.0b013e3181ac10a7

  42. 42.

    Hyman BT, et al. National Institute on Aging-Alzheimer’s association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1-13.

    Not in our library10.1016/j.jalz.2011.10.007

  43. 43.

    Kupsky WJ, Grimes MM, Sweeting J, Bertsch R, Cote LJ. Parkinson’s disease and megacolon: concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology. 1987;37:1253-1255.

    Not in our library10.1212/wnl.37.7.1253

  44. 44.

    Bloch A, Probst A, Bissig H, Adams H, Tolnay M. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neurobiol. Appl Neurol. 2006;32:284-295.

    Not in our library10.1111/j.1365-2990.2006.00727.x

  45. 45.

    Probst A, Bloch A, Tolnay M. New insights into the pathology of Parkinson’s disease: does the peripheral autonomic nervous system become central? Eur. J. Neurol. 2008;15:1-4.

    Not in our library10.1111/j.1468-1331.2008.02057.x

  46. 46.

    Beach TG, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010;119:689-702.

    Not in our library10.1007/s00401-010-0664-3

  47. 47.

    Stokholm MG, Danielsen HK, Hamilton-Dutoit SJ, Borghammer P. Pathological α-synuclein in gastrointestinal tissues from prodromal Parkinson disease patients. Ann. Neurol. 2016;79:940-949.

    Not in our library10.1002/ana.24648

  48. 48.

    Killinger BA, et al. The vermiform appendix impacts the risk of developing Parkinson’s disease. Sci. Transl. Med. 2018;10:eaar5280.

    Not in our library10.1126/scitranslmed.aar5280

  49. 49.

    Shannon K, Vanden Berghe P. The enteric nervous system in PD: gateway, bystander victim, or source of solutions. Cell Tiss. Res. 2018;373:313-326.

    Not in our library10.1007/s00441-018-2856-4

  50. 50.

    Braak H, et al. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging. 2003;24:197-211.

    Not in our library10.1016/s0197-4580(02)00065-9

  51. 51.

    Del Tredici K, Rüb U, de Vos RAI, Bohl JRE, Braak H. Where does Parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 2002;61:413-426.

    Not in our library10.1093/jnen/61.5.413

  52. 52.

    Del Tredici K, Hawkes CH, Ghebremedhin E, Braak H. Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson’s disease. Acta. Neuropathol. 2010;119:703-713.

    Not in our library10.1007/s00401-010-0665-2

  53. 53.

    Del Tredici K, Braak H. Spinal cord lesions in sporadic Parkinson’s disease. Acta. Neuropathol. 2012;124:643-664.

    Not in our library10.1007/s00401-012-1028-y

  54. 54.

    Ghebremedhin E, Del Tredici K, Langston JW, Braak H. Diminished tyrosine hydroxylase immunoreactivity in the cardiac conduction system and myocardium in Parkinson’s disease: an anatomical study. Acta. Neuropathol. 2009;118:777-784.

    Not in our library10.1007/s00401-009-0596-y

  55. 55.

    Hopkins DA, Bieger D, de Vente J, Steinbusch HWM. Vagal efferent projections: viscerotopy, neurochemistry and effects of vagotomy. Prog. Brain Res. 1996;107:79-96.

    Not in our library10.1016/s0079-6123(08)61859-2

  56. 56.

    Goyal RK, Hirano I. The enteric nervous system. N. Engl. J. Med. 1996;334:1106-1115.

    Not in our library10.1056/nejm199604253341707

  57. 57.

    Lack and relative lack of vagus nerve alpha-synuclein pathology in an autopsy series of 49 normal elderly and 18 with incidental Lewy body disease. American Association of Neuropathologists, Inc. Abstracts of the 93rd Annual Meeting June 8–11, 2017 Garden Grove, CA. J. Neuropathol. Exp. Neurol.76, Abstract 152 (2017). https://academic.oup.com/jnen/article/76/6/491/3832872.

    Not in our library

  58. 58.

    Beach TG, et al. Vagus nerve and stomach synucleinopathy in Parkinson’s disease, incidental Lewy body disease, and normal elderly subjects: Evidence against the “body-first” hypothesis. J. Parkinsons Dis. 2021;11:1833-1843.

    Not in our library10.3233/jpd-212733

  59. 59.

    Gelpi E, et al. Multiple organ involvement by alpha-synuclein pathology in Lewy body disorders. Mov. Disord. 2014;29:1010-1018.

    Not in our library10.1002/mds.25776

  60. 60.

    Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH. Is alpha-synuclein in the colon a biomarker for premotor 19. Parkinson’s disease? Evidence from 3 cases. Mov. Disord. 2012;27:716-719.

    Not in our library10.1002/mds.25020

  61. 61.

    Ito S, et al. Alpha-synuclein immunohistochemistry of gastrointestinal and biliary surgical specimens for diagnosis of Lewy body disease. Int J. Clin. Exp. Pathol. 2014;15:1714-1723.

    Not in our library

  62. 62.

    Borghammer P. How does Parkinson’s disease begin? Perspectives on neuroanatomical pathways, prions, and histology. Mov. Disord. 2018;33:48-57.

    Not in our library10.1002/mds.27138

  63. 63.

    Borghammer P, Van Den Berge N. Brain-first versus gut-first Parkinson’s disease: a hypothesis. J. Parkinsons Dis. 2019;9:S281-S295.

    Not in our library10.3233/jpd-191721

  64. 64.

    Del Tredici K, Braak H. A not entirely benign procedure: progression of Parkinson’s disease. Acta. Neuropathol. 2008;115:379-384.

    Not in our library10.1007/s00401-008-0355-5

  65. 65.

    Phillips RJ, Walter GC, Wilder SL, Baronowsky EA, Powley TL. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson’s disease? Neuroscience. 2008;153:733-750.

    Not in our library10.1016/j.neuroscience.2008.02.074

  66. 66.

    Chandra R, Hiniker A, Kuo YM, Nussbaum RL, Liddle RA. α-Synuclein in gut endocrine cells and its implications for Parkinson’s disease. JCI Insight. 2017;2:e92295.

    Not in our library10.1172/jci.insight.92295

  67. 67.

    Desplats P, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA. 2009;106:13010-13015.

    Not in our library10.1073/pnas.0903691106

  68. 68.

    George S, Rey NL, Reichenbach N, Steiner JA, Brundin P. α-Synuclein: the long distance runner. Brain Pathol. 2013;23:350-357.

    Not in our library10.1111/bpa.12046

  69. 69.

    Goedert M, Masuda-Suzukake M, Falcon B. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration. Brain. 2017;140:266-278.

    Not in our library10.1093/brain/aww230

  70. 70.

    Fenyi A, et al. Seeding propensity and characteristics of pathogenic αSyn assemblies in formalin-fixed human tissue from the enteric nervous system, olfactory bulb, and brainstem in cases staged for Parkinson’s disease. Cells. 2021;10:139.

    Not in our library10.3390/cells10010139

  71. 71.

    Recasens A, et al. Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology in neurodegeneration in mice and monkeys. Ann. Neurol. 2014;75:351-362.

    Not in our library10.1002/ana.24066

  72. 72.

    Chen F, et al. α-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular-mitral synaptic transmission. NPJ Parkinsons Dis. 2021;7:144.

    Not in our library10.1038/s41531-021-00259-7

  73. 73.
    Caudo‐rostral brain spreading of α‐synuclein through vagal connections · 2013
    No notice
  74. 74.

    Ulusoy A, et al. Brain-to-stomach transfer of α-synuclein via vagal preganglionic projections. Acta. Neuropathol. 2017;133:381-393.

    Not in our library10.1007/s00401-016-1661-y

  75. 75.
    Evidence for bidirectional and trans-synaptic parasympathetic and sympathetic propagation of alpha-synuclein in rats · 2019
    No notice
  76. 76.

    Holmqvist S, et al. Melki R. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta. Neuropathol. 2014;128:805-820.

    Not in our library10.1007/s00401-014-1343-6

  77. 77.

    Jackson RG. Anatomy of the vagus nerves in the region of the lower esophagus and the stomach. Anat. Rec. 1949;103:1-18.

    Not in our library10.1002/ar.1091030102

  78. 78.

    Travagli RA, Hermann GE, Browning KN, Rogers RC. Brainstem circuits regulating gastric function. Ann. Rev. Physiol. 2006;68:279-305.

    Not in our library10.1146/annurev.physiol.68.040504.094635

  79. 79.

    Braak H, Del Tredici K. Invited article: Nervous system pathology in sporadic Parkinson’s disease. Neurology. 2008;70:1916-1925.

    Not in our library10.1212/01.wnl.0000312279.49272.9f

  80. 80.

    Braak H, Del Tredici K. Potential pathways of abnormal tau and α-synuclein dissemination in sporadic Alzheimer’s and Parkinson’s diseases. Cold Spring Harb. Perspect. Biol. 2016;8:pii: a023630.

    Not in our library10.1101/cshperspect.a023630

  81. 81.

    Del Tredici K, Braak H. Sporadic Parkinson’s disease: development and distribution of α-synuclein pathology. Neuropathol. Appl. Neurobiol. 2016;42:33-50.

    Not in our library10.1111/nan.12298

  82. 82.

    Orimo S, Ghebremedhin E, Gelpi E. Peripheral and central autonomic nervous system: does the sympathetic or parasympathetic nervous system bear the brunt of the pathology during the course of sporadic PD? Cell Tiss. Res. 2018;373:267-286.

    Not in our library10.1007/s00441-018-2851-9

  83. 83.

    Breen DP, Halliday GM, Lang AE. Gut-brain axis and the spread of α-synuclein pathology: vagal highway or dead end? Mov. Disord. 2019;34:307-316.

    Not in our library10.1002/mds.27556

  84. 84.

    Horsager J, et al. Brain-first versus body-first Parkinson’s disease: a multimodal imaging case-control study. Brain. 2020;143:3077-3088.

    Not in our library10.1093/brain/awaa238

  85. 85.

    Boeve BF, et al. Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain. 2007;130:2770-2788.

    Not in our library10.1093/brain/awm056

  86. 86.

    Boeve BF, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep. Med. 2013;14:754-762.

    Not in our library10.1016/j.sleep.2012.10.015

  87. 87.

    Iranzo A, Toloso E, Gelpi E. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behavior disorder: an observational cohort study. Lancet Neurol. 2013;12:443-453.

    Not in our library10.1016/s1474-4422(13)70056-5

  88. 88.

    Sprenger FS, et al. Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder. Neurology. 2015;85:1761-1768.

    Not in our library10.1212/wnl.0000000000002126

  89. 89.

    Ehrminger M, et al. The coeruleus/subcoeruleus complex in idiopathic rapid eye movement sleep behaviour disorder. Brain. 2016;139:1180-1188.

    Not in our library10.1093/brain/aww006

  90. 90.

    Vilas D, et al. Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurol. 2016;15:708-718.

    Not in our library10.1016/s1474-4422(16)00080-6

  91. 91.

    Knudson K, et al. In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurol. 2018;17:618-628.

    Not in our library10.1016/s1474-4422(18)30162-5

  92. 92.

    Rees RN, Noyce AJ, Schrag A. The prodromes of Parkinson’s disease. Eur. J. Neurosci. 2019;49:320-327.

    Not in our library10.1111/ejn.14269

  93. 93.

    van de Berg WD, et al. Patterns of alpha-synuclein pathology in incidental cases and clinical subtypes of Parkinson’s disease. Parkinsonsim Relat. Disord. 2012;18:S28-S30.

    Not in our library10.1016/s1353-8020(11)70011-6

  94. 94.

    Coughlin DG, et al. Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but ‘failure to fit’ is highly dependent on staging system applied. Parkinsonism Relat. Disord. 2019;64:124-131.

    Not in our library10.1016/j.parkreldis.2019.03.023

  95. 95.

    Jellinger K. Is Braak staging valid for all types of Parkinson’s disease. J. Neural Transm. 2019;126:423-431.

    Not in our library10.1007/s00702-018-1898-9

  96. 96.

    Kalf J, de Swart BJ, Bloem BR, Munneke M. Prevalence of oropoharyngeal dysphagia in Parkinson’s disease: A meta-analysis. Parkinsonism Relat. Disord. 2012;18:311-315.

    Not in our library10.1016/j.parkreldis.2011.11.006

  97. 97.

    Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their responses to treatment in Parkinson’s disease. Neurology. 1989;39:1309-1314.

    Not in our library10.1212/wnl.39.10.1309

  98. 98.

    Bird M, Woodward MC, Gibson EM, Phyland DJ, Fonda D. Asymptomatic swallowing disorders in elderly patients with Parkinson’s disease: A description of findings on clinical examination and videofluoroscopy in sixteen patients. Age Ageing. 1994;23:251-254.

    Not in our library10.1093/ageing/23.3.251

  99. 99.

    Hammer MJ, Murphy CA, Abrams TM. Airway somatosensory deficits and dysphagia in Parkinson’s disease. J. Parkinson Dis. 2013;3:39-44.

    Not in our library10.3233/jpd-120161

  100. 100.

    Pflug C. Critical dysphagia is common in Parkinson disease and occurs even in early stages: A prospective cohort study. Dysphagia. 2018;33:41-50.

    Not in our library10.1007/s00455-017-9831-1

  101. 101.

    Patel B, et al. A comprehensive review of the diagnosis and treatment of Parkinson’s disease dysphagia and aspiration. Exp. Rev. Gastroenterol. Hepatol. 2020;14:411-424.

    Not in our library10.1080/17474124.2020.1769475

  102. 102.

    Burgos R, et al. ESPEN guidelines clinical nutrition in neurology. Clin. Nutr. 2018;37:354-396.

    Not in our library10.1016/j.clnu.2017.09.003

  103. 103.

    Mu L, et al. Altered pharyngeal muscles in Parkinson disease. J. Neuropathol. Exp. Neurol. 2012;71:520-530.

    Not in our library10.1097/nen.0b013e318258381b

  104. 104.

    Mu L, et al. Alpha-synuclein pathology and axonal degeneration of the peripheral motor nerves innervating pharyngeal muscles in Parkinson’s disease. J. Neuropathol. Exp. Neurol. 2013;72:119-129.

    Not in our library10.1097/nen.0b013e3182801cde

  105. 105.

    Mu L, et al. Parkinson’s disease affects peripheral sensory nerves in the pharynx. J. Neuropathol. Exp. Neurol. 2013;72:614-623-38.

    Not in our library10.1097/nen.0b013e3182965886

  106. 106.

    Schröder JB, et al. Substance P saliva reduction predicts pharyngeal dysphagia in Parkinson’s disease. Front. Neurol. 2019;10:386.

    Not in our library10.3389/fneur.2019.00386

  107. 107.

    Troche MS, Brandimore AE, Okun MS, Davenport PW, Hegland KW. Decreased cough sensitivity and aspiration in Parkinson disease. Chest. 2014;146:1294-1299.

    Not in our library10.1378/chest.14-0066

  108. 108.

    Warnecke, T., Dziewas, R. & Langmore, S. Neurogenic dysphagia. Originally published in German: Neurogene Dysphagien: Diagnostik und Therapie (W. Kohlhammer Verlag, Stuttgart, 2013; 2nd extended and rev. ed. 2018) (Springer, Cham, 2021).

    Not in our library

  109. 109.

    Warnecke T, et al. Neurogenic dysphagia: A systematic review and proposal of a classification system. Neurology. 2021;96:e876-e889.

    Not in our library10.1212/wnl.0000000000011350

  110. 110.

    Labeit B, et al. Oropharyngeal freezing and its relation to dysphagia—An analogy to freezing of gait. Parkinsonism Relat. Disord. 2020;75:1-6.

    Not in our library10.1016/j.parkreldis.2020.05.002

  111. 111.

    Troche MS, Okun MS, Rosenbek JC, Altmann LJ, Sapienza CM. Attentional resource allocation and swallowing safety in Parkinson’s disease: a dual task study. Parkinsonism Relat. Disord. 2014;20:439-443.

    Not in our library10.1016/j.parkreldis.2013.12.011

  112. 112.

    Labeit B, et al. Effect of cognitive and motor dual-task on oropharyngeal swallowing in Parkinson’s disease. Eur. J. Neurol. 2021;28:754-762.

    Not in our library10.1111/ene.14603

  113. 113.

    Fukae J, et al. Impact of residual drug in the pharynx on the delayed-on phenomenon in Parkinson’s disease patients. Mov. Disord. Clin. Pr. 2020;7:273-278.

    Not in our library10.1002/mdc3.12908

  114. 114.

    Buhmann C, et al. Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Parkinsonism Relat. Disord. 2019;62:51-56.

    Not in our library10.1016/j.parkreldis.2019.02.002

  115. 115.

    Lam K, et al. Simple clinical tests may predict severe oropharyngeal dysphagia in Parkinson’s disease. Mov. Disord. 2007;22:640-644.

    Not in our library10.1002/mds.21362

  116. 116.

    Cereda E, et al. Swallowing disturbances in Parkinson’s disease: a multivariate analysis of contributing factors. Parkinsonism Relat. Disord. 2014;20:1382-1387.

    Not in our library10.1016/j.parkreldis.2014.09.031

  117. 117.

    Cersósimo MG, et al. Hyposialorrhea as an early manifestation of Parkinson disease. Auton. Neurosci. 2009;150:150-151.

    Not in our library10.1016/j.autneu.2009.04.004

  118. 118.

    Nienstedt JC, et al. Drooling is no early sign of dysphagia in Parkinson’s disease. Neurogastroenterol. Motil. 2018;30:e13259.

    Not in our library10.1111/nmo.13259

  119. 119.

    Nóbrega AC, Rodrigues B, Melo A. Silent aspiration in Parkinson’s disease patients with diurnal sialorrhea. Clin. Neurol. Neurosurg. 2008;110:117-119.

    Not in our library10.1016/j.clineuro.2007.09.011

  120. 120.

    Manor Y, Giladi N, Cohen A, Fliss DM, Cohen JT. Validation of a swallowing disturbance questionnaire for detecting dysphagia in patients with Parkinson’s disease. Mov. Disord. 2007;22:1917-1921.

    Not in our library10.1002/mds.21625

  121. 121.

    Kalf JG, et al. Reproducibility and validity of patient-related assessment of speech, swallowing, and saliva control in Parkinson’s disease. Arch. Phys. Med Rehabil. 2011;92:1152-1158.

    Not in our library10.1016/j.apmr.2011.02.011

  122. 122.

    Simons JA, et al. Development and validation of a new screening questionnaire for dysphagia in early stages of Parkinson’s disease. Parkinsonism Relat. Disord. 2014;20:992-998.

    Not in our library10.1016/j.parkreldis.2014.06.008

  123. 123.

    Buhmann C, et al. Is the Munich dysphagia Test—Parkinson’s disease (MDT-PD) a valid screening tool for patients at risk of aspiration? Parkinsonism Relat. Disord. 2019;61:138-143.

    Not in our library10.1016/j.parkreldis.2018.10.031

  124. 124.

    Simons JA, et al. Multilingual validation of the first French version of Munich Dysphagia Test—Parkinson’s disease (MDT-PD) in the Luxembourg Parkinson’s study. Front Neurol. 2019;10:1180.

    Not in our library10.3389/fneur.2019.01180

  125. 125.

    Chaudhuri KR, Healy DG, Schapira AH, National Institute for Clinical Excellence. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol. 2006;5:235-245.

    Not in our library10.1016/s1474-4422(06)70373-8

  126. 126.

    Goetz CG, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson’s disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 2008;23:2129-2170.

    Not in our library10.1002/mds.22340

  127. 127.

    Nienstedt J, et al. Predictive clinical factors for penetration and aspiration in Parkinson’s disease. Neurogastroenterol. Motil. 2019;31:e13524.

    Not in our library10.1111/nmo.13524

  128. 128.

    Sampaio M, Argolo N, Melo A, Nóbrega AC. Wet voice as a sign of penetration/aspiration in Parkinson’s disease: does testing material matter? Dysphagia. 2014;29:610-615.

    Not in our library10.1007/s00455-014-9552-7

  129. 129.

    Kalf, H. et al. Guidelines for speech-language therapy in Parkinson’s disease. Nijmegen, the Netherlands/Miami (FL). (ParkinsonNet/NPF, U.S.A., 2011). https://www.parkinsonnet.com/discipline/speech-and-language.

    Not in our library

  130. 130.

    Pflug C, Niessen A, Buhmann C, Bihler M. Swallowing speed is no adequate predictor of aspiration in Parkinson’s disease. Neurogastroenterol. Motil. 2019;31:e13713.

    Not in our library10.1111/nmo.13713

  131. 131.

    Logemann JA. Evaluation and treatment of swallowing disorders. 1998.

    Not in our library

  132. 132.

    Langmore SE. Evaluation of oropharyngeal dysphagia: which diagnostic tool is superior? Curr. Opin. Otolaryngnol Head. Neck Surg. 2003;11:485-489.

    Not in our library10.1097/00020840-200312000-00014

  133. 133.

    Dziewas, R. et al. German guideline for neurogenic dysphagia (2020) https://dgn.org/wp-content/uploads/2013/01/030111_LL_Neurogene_Dysphagie_2020.pdf.

    Not in our library

  134. 134.

    Ciucci MR, et al. Early identification and treatment of communication and swallowing deficits in Parkinson disease. Semin Speech Lang. 2013;34:185-202.

    Not in our library10.1055/s-0033-1358367

  135. 135.

    Van Hooren MRA, et al. Treatment effects for dysphagia in Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 2014;20:800-807.

    Not in our library10.1016/j.parkreldis.2014.03.026

  136. 136.

    Melo A, Monteiro L. Swallowing improvement after levodopa treatment in idiopathic Parkinson’s disease: lack of evidence. Parkinsonsim Relat. Disord. 2013;19:279-281.

    Not in our library10.1016/j.parkreldis.2012.11.017

  137. 137.

    Sutton J. Dysphagia in Parkinson’s disease is responsive to levodopa. Parkinsonism Relat. Disord. 2013;19:282-284.

    Not in our library10.1016/j.parkreldis.2012.11.007

  138. 138.

    Chang MC, Park JS, Lee BJ, Park D. Effectiveness of pharmacologic treatment for dysphagia in Parkinson’s disease: a narrative review. Neurological Sci. 2021;42:513-519.

    Not in our library10.1007/s10072-020-04865-w

  139. 139.

    Monte F, da Silva-Júnior FP, Braga-Neto P, Nobre e Souza MA, de Bruin VM. Swallowing abnormalities and dyskinesia in Parkinson’s disease. Mov. Disord. 2005;20:457-462.

    Not in our library10.1002/mds.20342

  140. 140.

    Warnecke T, et al. Levodopa responsiveness of dysphagia in advanced Parkinson’s disease and reliability testing of the FEES-Levodopa-test. Parkinsonism Relat. Disord. 2016;28:100-106.

    Not in our library10.1016/j.parkreldis.2016.04.034

  141. 141.

    Hirano M, et al. Rotigotine transdermal patch improves swallowing in dysphagic patients with Parkinson’s disease. Dysphagia. 2015;30:452-456.

    Not in our library10.1007/s00455-015-9622-5

  142. 142.

    Hirano M, et al. Effects of the rotigotine transdermal patch versus oral levodopa on swallowing in patients with Parkinson’s disease. J. Neurol. Sci. 2019;15:404-405.

    Not in our library10.1016/j.jns.2019.07.003

  143. 143.

    Torti M, Bravi D, Vacca L, Stocchi F. Are all dopamine agonists essentially the same? Drugs. 2019;79:693-703.

    Not in our library10.1007/s40265-019-01103-2

  144. 144.

    Labeit B, et al. Effect of intestinal levodopa-carbidopa infusion on pharyngeal dysphagia: results from a retrospective pilot study in patients with Parkinson’s disease. Parkinsons Dis. 2020;11:4260501.

    Not in our library10.1155/2020/4260501

  145. 145.

    Yu H, Takahashi K, Bloom L, Quaynor SD, Xie T. Effect on Deep Brain Stimulation on swallowing function: A systematic review. Front Neurol. 2020;11:547.

    Not in our library10.3389/fneur.2020.00547

  146. 146.

    Chang, M. C., Park, J. S., Lee, B. J., Park, D. The effect of deep brain stimulation on swallowing function in Parkinson’s disease: A narrative review. Dysphagia. 10.1007/s00455-020-10214-y (2021).

    Not in our library10.1007/s00455-020-10214-y

  147. 147.

    Xie T, et al. Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology. 2015;84:415-420.

    Not in our library10.1212/wnl.0000000000001184

  148. 148.

    Xie T, et al. Long-term effect of low frequency stimulation of STN on dysphagia, freezing of gait and other motor symptoms in PD. J. Neurol. Neurosurg. Psychiatry. 2018;89:989-994.

    Not in our library10.1136/jnnp-2018-318060

  149. 149.

    Pflug C, et al. Impact of simultanous subthalamic and nigral stimulation on dysphagia in Parkinson’s disease. Ann. Clin. Transl. Neurol. 2020;7:628-638.

    Not in our library10.1002/acn3.51027

  150. 150.

    Heijnen BJ, Speyer R, Baijens LW, Bogaardt HC. Neuromuscular electrical stimulation versus traditional therapy in patients with Parkinson’s disease and oropharyngeal dysphagia: effects on quality of life. Dysphagia. 2012;27:336-345.

    Not in our library10.1007/s00455-011-9371-z

  151. 151.

    Baijens LW, et al. Surface electrical stimulation in dysphagic Parkinson patients: a randomized clinical trial. Laryngoscope. 2013;123:E38-E44.

    Not in our library10.1002/lary.24119

  152. 152.

    Park JS, Oh DH, Hwang NK, Lee JH. Effects of neuromuscular electrical stimulation in patients with Parkinson’s disease and dysphagia: A randomized, single-blind, placebo-controlled trial. NeuroRehab. 2018;42:457-463.

    Not in our library10.3233/nre-172306

  153. 153.

    Logemann JA, et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson’s disease. J. Speech Lang. Hear Res. 2008;51:173-183.

    Not in our library10.1044/1092-4388(2008/013)

  154. 154.

    Ayres AL, Jotz GP, Rieder CR, Olchik MR. Benefit from the chin-down maneuver in the swallowing performance ans self-perception of Parkinson’s disease patients. Parkinsons Dis. 2017;2017:e7460343.

    Not in our library10.1155/2017/7460343

  155. 155.

    Sharkawi AE, et al. Swallowing and voice effects on Lee Silverman Voice. J. Neurol. Neurosurg. Psychiatry. 2002;72:31-37.

    Not in our library10.1136/jnnp.72.1.31

  156. 156.

    Troche MS, et al. Aspiration and swallowing in Parkinson’s disease and rehabilitation with EMST: a randomized trial. Neurology. 2010;75:1912-1919.

    Not in our library10.1212/wnl.0b013e3181fef115

  157. 157.

    Claus I, et al. Expiratory muscle strength training for therapy of pharyngeal dysphagia in Parkinson’s disease. Mov. Disord. 2021;36:1815-1824.

    Not in our library10.1002/mds.28552

  158. 158.

    Manor Y, Mootanah R, Freud D, Giladi N, Cohen JT. Video-assisted swallowing therapy for patients with Parkinson’s disease. Parkinsonism Relat. Disord. 2013;19:207-211.

    Not in our library10.1016/j.parkreldis.2012.10.004

  159. 159.

    Athukorala RP, Jones RD, Sella O, Huckabee ML. Skill training for swallowing rehabilitation in patients with Parkinson’s disease. Arch. Phys. Med. Rehabil. 2014;95:1374-1382.

    Not in our library10.1016/j.apmr.2014.03.001

  160. 160.

    Jost WH, et al. SIAXI: Placebo-controlled, randomized, double-blind study of incobotulinumtoxin A for sialorrhea. Neurology. 2019;92:e1982-e1991.

    Not in our library10.1212/wnl.0000000000007368

  161. 161.

    Arbouw MEL, et al. Glycopyrrolate for sialorrhea in Parkinson’s disease: a randomized, double-blind, crossover trial. Neurology. 2010;74:1203-1207.

    Not in our library10.1212/wnl.0b013e3181d8c1b7

  162. 162.

    South AR, Somers SM, Jog MS. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology. 2010;74:1198-1202.

    Not in our library10.1212/wnl.0b013e3181d9002b

  163. 163.

    Marrinan S, Emmanuel AV, Burn DJ. Delayed gastric emptying in Parkinson’s disease. Mov. Disord. 2014;29:23-32.

    Not in our library10.1002/mds.25708

  164. 164.

    Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson’s disease. World J. Gastroenterol. 2016;22:5742-5752.

    Not in our library10.3748/wjg.v22.i25.5742

  165. 165.

    Doi H, et al. Plasma levodopa peak delay and impaired gastric emptying in Parkinson’s disease. J. Neurol. Sci. 2012;319:86-88.

    Not in our library10.1016/j.jns.2012.05.010

  166. 166.

    Sung HY, et al. The prevalence and patterns of pharyngoesophageal dysmotility in patients with early stage Parkinson’s disease. Mov. Disord. 2010;25:2361-2368.

    Not in our library10.1002/mds.23290

  167. 167.

    Suttrup I, et al. Esophageal dysfunction in different stages of Parkinson’s disease. Neurogastroenterol. Motil. 2017;29:e12915.

    Not in our library10.1111/nmo.12915

  168. 168.

    Pasricha PJ, Parkman HP. Gastroparesis: definitions and diagnosis. Gastroenterol. Clin. North Am. 2015;44:1-7.

    Not in our library10.1016/j.gtc.2014.11.001

  169. 169.

    Kahrilas PJ, et al. Smout AJ, The Chicago classification of esophageal motility disorders, v3.0. Neurogastroenterol. Motil. 2015;27:160-174.

    Not in our library10.1111/nmo.12477

  170. 170.

    Triadafilopoulos G, Gandhy R, Barlow C. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson’s disease. Parkinsonism Relat. Disord. 2017;44:33-37.

    Not in our library10.1016/j.parkreldis.2017.08.020

  171. 171.

    Derrey S, et al. Impact of deep brain stimulation on pharyngo-esophageal motility: a randomized cross-over study. Neurogastroenterol. Motil. 2015;27:1214-1222.

    Not in our library10.1111/nmo.12607

  172. 172.

    Alvarez-Berdugo D, et al. A comparative study on the therapeutic effect of TRPV1, TRPA1, and TRPM8 agonists on swallowing dysfunction associated with aging and neurological diseases. Neurogastroenterol. Motil. 2018;30:e13185.

    Not in our library10.1111/nmo.13185

  173. 173.

    Suntrup-Krueger S, et al. Effect of capsaicionoids on neurophysiological, biochemical and mechanical parameters of swallowing function. Neurotherapeutics. 2021;18:1360-1370.

    Not in our library10.1007/s13311-020-00996-2

  174. 174.

    Heetun ZS, Quigley EM. Gastroparesis and Parkinson’s disease: a systematic review. Parkinsonism Relat. Disord. 2012;18:433-440.

    Not in our library10.1016/j.parkreldis.2011.12.004

  175. 175.

    Gil RA, Hwynn N, Fabian T, Joseph S, Fernandez HH. Botulinum toxin type A for the treatment of gastroparesis in Parkinson’s disease patients. Parkinsonism Relat. Disord. 2011;17:285-287.

    Not in our library10.1016/j.parkreldis.2011.01.007

  176. 176.

    Arai F, et al. Subthalamic deep brain stimulation can improve gastric emptying in Parkinson’s disease. Brain. 2012;135:1478-1485.

    Not in our library10.1093/brain/aws086

  177. 177.

    Parkinson J. An essay on the shaking palsy. 1817.

    Not in our library10.1176/jnp.14.2.223

  178. 178.

    Jost WH. An update on the recognition and treatment of autonomic symptoms in Parkinson’s disease. Exp. Rev. Neurother. 2017;17:791-799.

    Not in our library10.1080/14737175.2017.1345307

  179. 179.

    Adler CH, Beach TG. Neuropathological basis of nonmotor manifestations of Parkinson’s disease. Mov. Disord. 2016;31:1114-1119.

    Not in our library10.1002/mds.26605

  180. 180.

    Knudsen K, Krogh K, Østergaard K, Borghammer P. Constipation in Parkinson’s disease: subjective symptoms, objective markers, and new perspectives. Mov. Disord. 2017;32:94-105.

    Not in our library10.1002/mds.26866

  181. 181.

    Parkinson Study Group. A randomized trial of relamorelin for constipation in Parkinson’s disease (MOVE-PD): Trial results and lessons learned. Parkinsonism Relat. Disord. 2017;37:101-105.

    Not in our library10.1016/j.parkreldis.2017.02.003

  182. 182.

    Jost WH. Autonome Regulationsstörungen beim Parkinson Syndrom [Disorders of autonomic regulation in Parkinson syndrome]. Fortschr. Neurol. Psychiatr. 1995;63:194-205.

    Not in our library10.1055/s-2007-996616

  183. 183.

    Barone P, et al. The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov. Disord. 2009;24:1641-1649.

    Not in our library10.1002/mds.22643

  184. 184.

    Abbott RD, et al. Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology. 2001;57:456-464.

    Not in our library10.1212/wnl.57.3.456

  185. 185.

    Stirpe P, Hoffman M, Badiali D, Colosimo C. Constipation: an emerging risk factor for Parkinson’s disease? Eur. J. Neurol. 2016;23:1606-1613.

    Not in our library10.1111/ene.13082

  186. 186.

    Svensson E, Henderson VW, Borghammer P, Horváth-Puhó E, Sørensen HT. Constipation and risk of Parkinson’s disease: A Danish population-based cohort study. Parkinsonism Relat. Disord. 2016;28:18-22.

    Not in our library10.1016/j.parkreldis.2016.05.016

  187. 187.

    Pierantozzi M, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66:1824-1829.

    Not in our library10.1212/01.wnl.0000221672.01272.ba

  188. 188.

    Savica R, et al. Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology. 2009;73:1752-1758.

    Not in our library10.1212/wnl.0b013e3181c34af5

  189. 189.

    Gage H, et al. Correlates of constipation in people with Parkinson’s. Parkinsonism Relat. Disord. 2011;17:106-111.

    Not in our library10.1016/j.parkreldis.2010.11.003

  190. 190.

    Camacho M, et al. Early constipation predicts faster dementia onset in Parkinson’s disease. NPJ Parkinsons Dis. 2021;7:45.

    Not in our library10.1038/s41531-021-00191-w

  191. 191.

    García Roca, L. et al. COPPADIS Study Group. Constipation predicts cognitive decline in Parkinson’s disease: results from the COPPADIS Cohort at 2-year follow-up and comparison with a control group. J. Parkinsons Dis. 10.3233/JPD-212868 (2021).

    Not in our library10.3233/jpd-212868

  192. 192.

    Kenna JE, et al. Characterization of gastrointestinal symptom type and severity in Parkinson’s disease: A case-control study in an Australian cohort. Mov. Disord. Clin. Pr. 2021;8:245-253.

    Not in our library10.1002/mdc3.13134

  193. 193.

    Lundin E, et al. Segmental colonic transit studies: Comparison of a radiological and a scintigraphic method. Colorectal Dis. 2007;9:344-351.

    Not in our library10.1111/j.1463-1318.2006.01153.x

  194. 194.

    Agachan F, Pfeifer J, Wexner SD. Defecography and proctography. Results of 744 patients. Dis. Colon Rectum. 1996;39:899-905.

    Not in our library10.1007/bf02053989

  195. 195.

    Jost WH, Schrank B, Herold A, Leiß O. Functional outlet obstruction: Anismus, spastic pelvic floor syndrome, and dyscoordination of the voluntary sphincter muscles. Scand. J. Gastroenterol. 1999;34:449-453.

    Not in our library10.1080/003655299750026146

  196. 196.

    Barichella M, et al. Probiotics and prebiotic fiber for constipation associated with PD. Neurology. 2016;87:1274-1280.

    Not in our library10.1212/wnl.0000000000003127

  197. 197.

    Zangaglia R, et al. Macrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled study. Mov. Disord. 2007;22:1239-1244.

    Not in our library10.1002/mds.21243

  198. 198.

    Zesiewicz TA, et al. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2010;74:924-931.

    Not in our library10.1212/wnl.0b013e3181d55f24

  199. 199.

    Tan AH, et al. Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study. Neurology. 2021;96:e772-e782.

    Not in our library10.1212/wnl.0000000000010998

  200. 200.

    Liu Z, et al. Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov. Disord. 2005;20:680-686.

    Not in our library10.1002/mds.20387

  201. 201.

    Freitas ME, Alqaraawi A, Lang AE, Liu LWC. Linaclotide and prucalopride for management of constipation in patients with parkinsonism. Mov. Disord. Clin. Pr. 2018;5:218-220.

    Not in our library10.1002/mdc3.12577

  202. 202.

    Bassotti G, Usai Satta P, Bellini M. Plecanatide for the treatment of chronic idiopathic constipation in adult patients. Expert Rev. Clin. Pharm. 2019;12:1019-1026.

    Not in our library10.1080/17512433.2019.1670057

  203. 203.

    Ondo WG, et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78:1650-1654.

    Not in our library10.1212/wnl.0b013e3182574f28

  204. 204.
    Functional implications of microbial and viral gut metagenome changes in early stage L-DOPA-naïve Parkinson’s disease patients · 2017
    Corrected
  205. 205.

    Pietrucci D, et al. Dysbiosis of gut microbiota in a selected population of Parkinson’s patients. Parkinsonism Relat. Disord. 2019;65:124-130.

    Not in our library10.1016/j.parkreldis.2019.06.003

  206. 206.
    Effect of Parkinson’s disease and related medications on the composition of the fecal bacterial microbiota · 2019
    No notice
  207. 207.

    Chapelet G, Leclair-Visonneau L, Clairembault T, Neunlist M, Derkinderen P. Can the gut be the missing piece in uncovering PD pathogenesis? Parkinsonism Relat. Disord. 2020;59:26-31.

    Not in our library10.1016/j.parkreldis.2018.11.014

  208. 208.

    Cryan JF, O’Riordan KJ, Sandhu K, Peterson V, Dinan TG. The gut microbiome in neurological disorders. Lancet Neurol. 2020;19:179-194.

    Not in our library10.1016/s1474-4422(19)30356-4

  209. 209.

    Metta, V. et al. Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. J. Neurol.10.1007/s00415-021-10567-w (2021).

    Not in our library10.1007/s00415-021-10567-w

  210. 210.

    Weis S, et al. Association between Parkinson’s disease and the faecal eukaryotic microbiota. NPJ Parkinsons Dis. 2021;7:101.

    Not in our library10.1038/s41531-021-00244-0

  211. 211.
    The nasal and gut microbiome in Parkinson's disease and idiopathic rapid eye movement sleep behavior disorder · 2017
    No notice
  212. 212.

    Does the truth lie within the gut? Investigating the gut microbiome in an Australian cohort of Parkinson’s disease patients. American Academy of Neurology, Abstracts of the 72nd Annual Meeting April 25-May 1, 2020 Toronto. Ontario. Neurology94, Abstract 1438, https://n.neurology.org/content/94/15_Supplement/1438 (2020)..

    Not in our library

  213. 213.

    Devos D, et al. Colonic inflammation in Parkinson’s disease. Neurobiol. Dis. 2013;50:42-48.

    Not in our library10.1016/j.nbd.2012.09.007

  214. 214.

    Nielsen SD, Pearson NM, Seidler K. The link between the gut microbiota and Parkinson’s disease: A systematic mechanism review with focus on α-synuclein transport. Brain Res. 2021;1769:147609.

    Not in our library10.1016/j.brainres.2021.147609

  215. 215.

    Hill-Burns EM, et al. Parkinson’s disease and Parkinson’s disease medications have distinct signatures of the gut microbiome. Mov. Disord. 2017;32:739-749.

    Not in our library10.1002/mds.26942

  216. 216.
    Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease · 2011
    No notice
  217. 217.

    de Vos WM, de Vos EA. Role of the intestinal microbiome in health and disease: from correlation to causation. Nutr. Rev. 2012;70:S45-S56.

    Not in our library10.1111/j.1753-4887.2012.00505.x

  218. 218.
    The prion hypothesis in Parkinson's disease: Braak to the future · 2013
    No notice
  219. 219.

    Stolzenberg E, et al. A role for neuronal alpha-synuclein in gastrointestinal immunity. J. Innate Immun. 2017;9:456-463.

    Not in our library10.1159/000477990

  220. 220.

    Sulzer D, et al. T cells from patients with Parkinson’s disease recognize α-synuclein peptides. Nature. 2017;546:656-661.

    Not in our library10.1038/nature22815

  221. 221.
    Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson’s disease · 2019
    No notice
  222. 222.

    van Kessel SP, Auvinen P, Scheperjans F, El Aidy S. Gut bacterial tyrosine decarboxylase associates with clinical variables in a longitudinal cohort study of Parkinson’s disease. NPJ Parkinsons Dis. 2021;7:115.

    Not in our library10.1038/s41531-021-00260-0

  223. 223.

    Keshavarzian A, Engen P, Bonvegna S, Cilia R. The gut microbiome in Parkinson’s disease: A culprit or a bystander? Prog. Brain Res. 2020;252:357-450.

    Not in our library10.1016/bs.pbr.2020.01.004

  224. 224.

    Seguella L, Sarnelli G, Esposito G. Leaky gut, dysbiosis, and enteric glia activation: the trilogy behind the intestinal origin of Parkinson’s disease. Neural Regen. Res. 2020;15:1037-1038.

    Not in our library10.4103/1673-5374.270308

  225. 225.

    Gorecki AM, et al. Single nucleotide polymorphisms associated with gut homeostasis influence risk and age-at-onset of Parkinson’s disease. Front. Aging Neurosci. 2020;12:603849.

    Not in our library10.3389/fnagi.2020.603849

  226. 226.

    Bedarf JR, et al. Das Darm-Mikrobiom bei der Parkinson-Krankheit [The gut microbiome in Parkinson’s disease]. Nervenarzt. 2019;90:160-166.

    Not in our library10.1007/s00115-018-0601-6

  227. 227.
    Diet in Parkinson's Disease: Critical Role for the Microbiome · 2019
    No notice
  228. 228.

    Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell. 2017;167:1469-1480.

    Not in our library10.1016/j.cell.2016.11.018

  229. 229.
    Fecal Microbiota Transplantation in Neurological Disorders · 2020
    No notice
  230. 230.

    Segal A, Zlotnik Y, Moyal-Atias K, Abuhasira R, Ifergane G. Fecal microbiota transplant as a potential treatment for Parkinson’s disease—A case series. Clin. Neurol. Neurosurg. 2021;207:106791.

    Not in our library10.1016/j.clineuro.2021.106791

  231. 231.

    Fecal Microbiota Transplantation for Parkinson’s Disease. https://clinicaltrials.gov/ct2/show/NCT03808389. Accessed 31 Dec 2021.

    Not in our library

  232. 232.

    Okino Y, et al. Root of the small-bowel mesentery: correlative anatomy and CT features of pathologic conditions. Radiographics. 2001;21:1475-1490.

    Not in our library10.1148/radiographics.21.6.g01nv121475

Cited by papers we hold 2

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.